Merck & Co's Keytruda Disappoints In Small-Cell Lung Cancer
Triple-Negative Breast Cancer The Next Big Therapeutic Opportunity?
In top-line final Phase III results from KEYNOTE-604, Keytruda improves PFS but not OS when combined with chemotherapy for the first-line treatment of small-cell lung cancer.
